Elevation Oncology Valuation
| ELEVDelisted Stock | USD 0.37 0.00 0.00% |
Elevation Oncology seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Elevation Oncology from reviewing the firm fundamentals such as Current Valuation of (27.78 M), shares owned by insiders of 0.35 %, and Shares Owned By Institutions of 59.72 % as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Elevation Oncology's price fluctuation is very steady at this time. Calculation of the real value of Elevation Oncology is based on 3 months time horizon. Increasing Elevation Oncology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Elevation stock is determined by what a typical buyer is willing to pay for full or partial control of Elevation Oncology. Since Elevation Oncology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Elevation Stock. However, Elevation Oncology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.37 | Real 0.3 | Hype 0.37 |
The intrinsic value of Elevation Oncology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Elevation Oncology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Elevation Oncology helps investors to forecast how Elevation stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Elevation Oncology more accurately as focusing exclusively on Elevation Oncology's fundamentals will not take into account other important factors: Elevation Oncology Total Value Analysis
Elevation Oncology is currently forecasted to have valuation of (27.78 M) with market capitalization of 21.63 M, debt of 31.13 M, and cash on hands of 122.54 M. The negative valuation of Elevation Oncology may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Elevation Oncology fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(27.78 M) | 21.63 M | 31.13 M | 122.54 M |
Elevation Oncology Asset Utilization
One of the ways to look at asset utilization of Elevation is to check how much profit was generated for every dollar of assets it reports. Elevation Oncology shows a negative utilization of assets of -0.3 percent, losing $0.002986 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Elevation Oncology shows how discouraging it operates for each dollar spent on its assets.Elevation Oncology Ownership Allocation
Elevation Oncology holds a total of 59.25 Million outstanding shares. Over half of Elevation Oncology's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Elevation Oncology Profitability Analysis
Net Loss for the year was (44.48 M) with profit before overhead, payroll, taxes, and interest of 0.About Elevation Oncology Valuation
Our relative valuation model uses a comparative analysis of Elevation Oncology. We calculate exposure to Elevation Oncology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Elevation Oncology's related companies.Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York. Elevation Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 40 people.
Elevation Oncology Growth Indicators
Investing in growth stocks can be very risky. If the company such as Elevation Oncology does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 57.3 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Elevation Stock
If you are still planning to invest in Elevation Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Elevation Oncology's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |